10 February 2014 - Alimera Sciences, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Scottish Medicines Consortium (SMC), after completing its assessment and review of a simple patient access scheme, has accepted Iluvien for restricted use within the National Health Service (NHS) Scotland.
The advice issued by the SMC provides NHS Scotland patients considered insufficiently responsive to available therapies with access to Iluvien, the only sustained-release treatment for chronic diabetic macular edema (DME). The advice is restricted to those who have a pseudophakic eye, meaning the eye has already undergone cataract surgery. In addition, retreatment with Iluvien is predicated on a positive response to, and subsequent need for the product.

For more details, go to: http://investor.alimerasciences.com/releasedetail.cfm?ReleaseID=824480